Colgate restructuring
This article was originally published in The Tan Sheet
Executive Summary
Firm is on track with its current restructuring initiative, which is expected to result in savings of $40 mil.-$50 mil. this year, CEO Reuben Mark reports during a presentation at the Sanford C. Bernstein Strategic Decisions Conference June 1. The plan, announced in December, is aimed at generating savings of $250 mil.-$300 mil. over four years (1"The Tan Sheet" Dec. 13, 2004, p. 14). Colgate will maintain its strategy of focusing on limited categories such as oral care, while "play[ing] down" or divesting other segments, Mark said. The firm will continue to back its oral care franchise with promotional spending despite escalating material costs, the exec notes...
You may also be interested in...
Colgate Strategic Restructuring Aimed At Boosting Ad Spend, Earnings
Colgate is undertaking a four-year restructuring plan aimed at increasing the company's profits by generating annual savings of $250 mil.-$300 mil. after taxes by the fourth year
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.